Finding better treatments for a rare and aggressive cancer called NUT carcinoma
Official title: Overcoming Limitations of BETInhibition in NUT Carcinoma
Funded at Brigham and Women's Hospital · NIH-10984705 · Data updated 2026-11-12
This study is looking at a rare and tough type of cancer called NUT carcinoma, mainly affecting young people, to find out how certain proteins help it grow, with the goal of discovering new ways to treat it.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $558,775 |
| NIH project number | 1U01CA294062-01 |
| Project ID | NIH-10984705 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adolescents and young adults diagnosed with NUT carcinoma.
✕Less likely to help
Patients with other types of cancer or those who do not have NUT carcinoma may not benefit from this research.
What this research studies
This research focuses on NUT carcinoma, a rare and aggressive cancer primarily affecting adolescents and young adults, which currently has no effective treatments. The team aims to understand how certain proteins, specifically BRD4-NUT, drive the growth of this cancer by altering the structure of DNA and gene expression. They will explore new therapeutic targets by identifying other factors that work alongside BRD4-NUT to promote cancer growth. By using advanced techniques like CRISPR and studying the 3D structure of chromatin, the researchers hope to develop more effective treatment strategies for patients with NUT carcinoma.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better survival rates for patients with NUT carcinoma.
How similar studies have gone: Previous research has shown promise in using BET inhibitors for treating various cancers, but this specific approach to NUT carcinoma is novel.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: French, Christopher a — Brigham and Women's Hospital
- Study coordinator: French, Christopher a
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Understanding how bladder cancer starts in Veterans exposed to carcinogens and the role of PPAR-g in early bladder cancer
A research team is studying how bladder cancer begins and progresses in Veterans exposed to carcinogens, focusing on the PPAR-γ protein and early precancerous changes.
-
Adding PSMA PET/CT imaging to liver cancer care for veterans
This project tests a new PET imaging approach to help diagnose and guide treatment for liver cancer in veterans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.